New hope for Tough-to-Treat leukemia: first patients test experimental drug
NCT ID NCT06285890
Summary
This is an early-stage study to find a safe dose of a new oral drug, HC-7366, for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. Researchers will enroll about 18 participants to check for side effects and see if the drug shows any signs of helping control the cancer. The study will also measure how the drug behaves in the body and interacts with other common medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.